Email this article Development and validation of methods of quantitative determination of biologically active compound n-(2-[4-oxo-3(4h)-quinazolinyl]propionyl)guanidine
- Authors: Kompantseva E.V.1, Lutsenko D.N.1, Glushko A.A.1
-
Affiliations:
- Pyatigorsk Medical and Pharmaceutical Institute, a Branch of Volgograd State Medical University
- Issue: Vol 19, No 5-6 (2019)
- Pages: 122-127
- Section: Clinical Medicine
- URL: https://journals.rcsi.science/2410-3764/article/view/34215
- DOI: https://doi.org/10.17816/2072-2354.2019.19.3.122-127
- ID: 34215
Cite item
Full Text
Abstract
This paper presents the results of the selection and justification of the conditions for determination of a new biologically active compound (BAC) VMA-13-15, which is N-(2-[4-oxo-3(4H)-quinazolinyl]propionyl)guanidine bymeans of the spectrophotometry. By using the calculated values of BAC ionization constants, it was proposed to use purified water as a solvent. The maximum light absorption at 266 nm was chosen as the analytical wavelength. This was justified by the fact that in aqueous solutions 99% BAC are in the molecular form, which allows to determine it with the error limit of 1.29%, and with the least amount of dilutions. The study showed that the proposed method is specific and linear in the analytical concentration of 0.001–0.004%, as well as it is precise and correct, which confirms the possibility of its use for quantitative determination.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Evgenia V. Kompantseva
Pyatigorsk Medical and Pharmaceutical Institute, a Branch of Volgograd State Medical University
Author for correspondence.
Email: pharmachemistry@mail.ru
Doctor of Pharmaceutical Sciences, Professor, Department of Pharmaceutical and Toxicological Chemistry
Russian Federation, PyatigorskDaria N. Lutsenko
Pyatigorsk Medical and Pharmaceutical Institute, a Branch of Volgograd State Medical University
Email: Lucenkodasha95@mail.ru
Postgraduate student, Department of Pharmaceutical and Toxicological Chemistry
Russian Federation, PyatigorskAlexander A. Glushko
Pyatigorsk Medical and Pharmaceutical Institute, a Branch of Volgograd State Medical University
Email: pharmachemistry@mail.ru
Candidate of Pharmaceutical Sciences, Senior Lecturer, Department of Inorganic, Physical, and Dispersoidology
Russian Federation, PyatigorskReferences
- Альберт А., Сержент Е. Константы ионизации кислот и оснований / Пер. с англ. Е.Ю. Беляева, В.И. Зайонца, И.Я. Квитко, Б.В. Пассета, под ред. Б.А. Порай-Кошица. – Москва, Ленинград: Химия, 1964. – 380 c. [Albert A, Sergeant E. Konstanty ionizatsii kislot i osnovaniy. Transl. from Engl. E.Yu. Belyaev, V.I. Zajonts, I.Ya. Kvitko, B.V. Passet, ed. by B.A. Poray-Koshits. Moscow, Leningrad: Khimiya; 1964. 380 р. (In Russ.)]
- Федеральная электронная медицинская библиотека. Государственная фармакопея РФ. XIV издание. Т. IV. – М., 2018. – 1832 с. [Federal electronic medical library. The State Pharmacopoeia of the Russian Federation. XIV edition. Vol. IV. Moscow; 2018. 1832 р. (In Russ.)]. Доступно по: http://www.femb.ru/femb/pharmacopea.php. Ссылка активна на 09.09.2019.
- Патент РФ на изобретение RU № 2622638 C1. Петров В.И., Тюренков И.Н., Озеров А.А., и др. Производные хиназолин-4(3H)-она, обладающие нейро- и кардиопротекторной активностью. [Patent RUS No. 2622638 C1. Petrov VI, Tyurenkov IN, Ozerov AA, et al. Proizvodnye khinazolin-4(3H)-ona, obladayushchie neyro- i kardioprotektornoy aktivnost’yu. (In Russ.)]. Доступно по: https://yandex.ru/patents/doc/RU2622638C1_20170619. Ссылка активна на 14.09.2019.
- Шпрах З.С., Игнатьева Е.В., Ярцева И.В., и др. Разработка и валидация методики количественного определения цифетрилина в таблетках // Российский биотерапевтический журнал. – 2016. – Т. 15. – № 3. – С. 55–61. [Shprakh ZS, Ignat’yeva YeV, Yartseva IV, et al. Development and validation of cyphetrylin assay in tablets. Rossiyskiy bioterapevticheskiy zhurnal. 2016;15(3):55-61. (In Russ.)]
- Ravichandran V, Shalini S, Sundram KM, Harish R. Validation of analytical methods strategies and importance. Int J Pharm Pharm Sci. 2010;2:18-22.
Supplementary files
